pre nr - hmmm, page-4

Not a great reaction from the market hey. Would've been a good trigger point to exit for short term traders who'd made up to 50% in the past week from 1.2c to 1.8c.

This is a pretty significant announcement imo. The recent Company half year report (29th Feb) on page 4 mentions BN006 as having blockbuster potential. The financial definition of blockbuster is "an extremely popular drug that generates annual sales of at least $1 billion for the company that creates it." $1b annually = nice target.

Bone has a pretty good range of projects, 2 late stage projects (Capsitonin and Capthymone) which are based on existing chemical formula and so can follow the very fast 505 approval route and get through phase 3 trials quickly. And BN006 which is a new drug that has massive potential but is in early stages.

However imo the most important part of the annc today is that each of the 3 projects separately has current partnering opportunities and the company is in discussion with these partners. Some of the companies Bone mentioned in their investor presentation on 23rd Feb were Merck, GlaxoSmithKline, Pfizer, Sanofi Aventis, Lilly etc. A partnering interest in Bone would be peanuts for these big fellas with huge potential return for them and Bone, and an instant re-rating for Bone.